

Substitute for form 1449/PTO			<b>Complete if known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Application Number</b>	10/540,084-Conf. #7531	
			<b>Filing Date</b>	April 7, 2006	
			<b>First Named Inventor</b>	Mary Collins	
			<b>Art Unit</b>	1644	
			<b>Examiner Name</b>	I. I. Ouspenski	
<b>Sheet</b>	1	of	3	<b>Attorney Docket Number</b>	M0274.70042US02

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US 2005/0180969	08/18/2005	Hardy et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number-Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† <sup>4</sup>
		WO 04/0568754 A1	07/08/2004	Wyeth, et al.		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			† <sup>2</sup>
		ANASPEC Online Catalog (Catalog No. 54662), "Anti-PDCD1 (CT)." <a href="http://www.anaspec.com/pdfs/54662.pdf">www.anaspec.com/pdfs/54662.pdf</a>			
		ANSARI et al., 2003, "The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice," J. Exp. Med. 198: 63-69.			
		BENNETT et al., 2003, "Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL15 Responses," J. Immunol. 170: 711-718.			
		BLAZER et al., 2002, "PD-1 Engagement Provides an Inhibitory Signal Which Downregulates T Cell Alloresponses In Vivo," Blood 100: 72a, Abstract No. 261.			
		CARRENO et al., 2002, "The B7 Family of Ligands and Its Receptors: New Pathways for Costimulation and Inhibition of Immune Response," Annu. Rev. Immunol. 20: 29-53.			
		CURETECH Press Release, 2007, "CureTech announces receipt of a Notice of Allowance from the US Patent and Trademark Office"			
		CURETECH, <a href="http://www.curetechbio.com/?TemplateID=29&amp;PageID=145&amp;TemplateType=14">http://www.curetechbio.com/?TemplateID=29&amp;PageID=145&amp;TemplateType=14</a>			
		DAVIES et al., 1996, "Affinity Improvement of Single Antibody VH Domains; Residues in All Three Hypervariable Regions Affect Antigen Binding," Immunotechnology 2: 169-179.			
		DE KRUIF et al., 1995, "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions," J. Mol. Biol. 248, pp. 97-105.			
		DESMYTER A. et al., 2001, "Antigen Specificity and High Affinity Binding Provided by One Single Loop of a Camel Single-Domain Antibody", The Journal of Biological Chemistry, Vol.			

<b>EXAMINER:</b>	<b>DATE CONSIDERED:</b>
------------------	-------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

† a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

1210262.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //I.O./

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/540,084-Conf. #7531	
			Filing Date	April 7, 2006	
			First Named Inventor	Mary Collins	
			Art Unit	1644	
			Examiner Name	I. I. Ouspenski	
Sheet	2	of	3	Attorney Docket Number	M0274.70042US02

	276, No. 28, pp. 26285-26290.	
	HOLLING, T. et al., 2004, "Function and Regulation of MHC Class II Molecules in T-Lymphocytes: Of Mice and Men," <i>Human Immunology</i> 65: 282-290.	
	ISHIDA Y. et al., 1992, "Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death," <i>EMBO Journal</i> , 11:11, pp. 3887-3895	
	JIRHOLT. P. et al., 1998, "Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework," <i>Gene</i> , 215, pp 471-476.	
	LADNER et al., 2007, "Antibodies cut down to size," <i>Nat Biotechnol</i> , Aug;25(8):875-7.	
	LEVI et al., 1993, "A Complementarity-Determining Region Synthetic Peptide Acts as a Miniantibody and Neutralizes Human Immunodeficiency Virus Type 1 In Vitro," <i>Proc. Natl. Acad. Sci.</i> , 90: 4374-4378.	
	MARKS, J. D. et al., 1992, "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>BioTechnology</i> , Vol. 10, pp. 779783.	
	MAYNARD J. and GEORGIU G., 2000, "Antibody Engineering," <i>Annu. Rev. Biomed. Eng.</i> 02 pp. 339-76.	
	NISHIMURA, H. et al., 1999, "Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor," <i>Immunity</i> . Vol. 11, pp. 141-151.	
	QIU et al., 2007, "Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting," <i>Nat Biotechnol</i> , 2007 Aug;25(8):921-9. Epub.	
	REITER, Y et al., 1999, "An Antibody Single-domain Phage Display Library of a Native Heavy Chain Variable Region: Isolation of Functional Single-domain VH Molecules with a Unique Interface," <i>J. Mol. Biol.</i> 290, pp. 685-698.	
	SÖDERLIND, E. et al., 2000, "Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries," <i>Nature Biotechnology</i> , Vol 18, pp. 852-856.	
	SÖDERLIND, E. et al., 1999, "Complementarity-determining region (CDR) implantation: a theme of recombination," <i>Immunotechnology</i> , 4, pp. 279-285.	
	WARD et al., 1989, "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from <i>Escherichia Coli</i> ," <i>Nature</i> 341: 544-546	
	WELLING, et al., 1991, "A Ten-Residue Fragment of an Antibody (Mini-Antibody) Directed Against Lysozyme as Ligand in Immunoaffinity Chromatography," <i>J. Chromatography</i> , 548: 235-242.	
	WILLIAMS et al., 1989, "Development of Biologically Active Peptides Based on Antibody Structure," <i>Proc. Natl. Acad. Sci.</i> 86: 5537-5541.	
	XU J. L. and DAVIS M. M., "Diversity in the CDR3 Region of V <sub>H</sub> is Sufficient for Most Antibody Specificities," <i>Immunity</i> , Vol 13, pp. 37-45.	
	ZHONG, X. et al., 2004, "Suppression of expression and function of negative immune	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

"a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications)."

1210262.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //O.O//

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/540,084-Conf. #7531
				Filing Date	April 7, 2006
				First Named Inventor	Mary Collins
				Art Unit	1644
				Examiner Name	I. I. Ouspenski
Sheet	3	of	3	Attorney Docket Number	M0274.70042US02

		regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger." Int'l Immunology, 16:8, pp. 1181-1188.	
		Accession No. Q15116 (2003)	
		Accession No. NM_008798 (2003)	

EXAMINER:  /Iliia Ouspenski/	DATE CONSIDERED:  06/05/2008
------------------------------------	------------------------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

1210262.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. //I.O./